Resource library - Median Technologies

Immunotherapies display novel response patterns that affect the design of imaging based studies and the subsequent evaluation of imaging data. Applying traditional chemotherapy-based response assumptions to immunotherapy trials can result in inaccurate interpretation of response, premature therapy termination, and unnecessary removal of subjects from a trial. Our unique solutions for medical image analysis and management and iBiopsy® for imaging phenotyping, together with our global team of experts, are advancing the development of new drugs and diagnostic tools to monitor disease and assess response to therapy.

Yan Liu [1] [2] , Elton Rexhepaj [3] , Afef Baili Laya [3] , Corinne Ramos [3] , Hubert Beaumont [1] , Nozha Boujemaa [3] , Anthony Lockett [2] - Affiliations [1] Medical Affairs, Median Technologies, Valbonne, France, [2] Bioscience , King's College London, London, UK - [3] iBiopsy® Business Unit, Median Technologies, Valbonne, France

Poster presented at The Liver Meeting, organized by the American Association for the Study of Liver Diseases, Nov 13-16, 2020 – Virtual experience

Based on a meta-analysis, the poster analyses radiomics contribution to liver cancer recurrence prediction and shows how radiomics are approaching their limits for predicting disease outcome.  Imaging phenomics, an emerging technology implemented in Median’s iBiopsy® platform may provide the framework to explore new associations between phenotypes which are currently not feasible using traditional radiomic workflows.